Cheng Du Sheng Nuo Biotec Co., Ltd. () Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

PRE-TAX PROFIT(Q) At CNY 47.22 MM has Grown at 1,080.85%
NET PROFIT(Q) At CNY 41.86 MM has Grown at 687.51%
ROCE(HY) Highest at 12.5%

With ROE of 11.78%, it has a fair valuation with a 5.99 Price to Book Value

Market Beating performance in long term as well as near term

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

CNY 5,944 Million (Mid Cap)

P/E

51.00

Industry P/E

Dividend Yield

0.00%

Debt Equity

0.27

Return on Equity

11.78%

Price to Book

5.99

Revenue and Profits:

Net Sales:

151 Million

(Quarterly Results - Jun 2025)

Net Profit:

42 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

4.23%

6 Months

29.31%

1 Year

103.0%

2 Years

111.08%

3 Years

229.26%

4 Years

127.18%

5 Years

0.0%

Cheng Du Sheng Nuo Biotec Co., Ltd. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

Cheng Du Sheng Nuo Biotec Hits Day High with 6.74% Surge

Cheng Du Sheng Nuo Biotec Co., Ltd. has shown notable stock activity, achieving an intraday high and reflecting strong performance in the pharmaceuticals sector. Over the past year, the company has significantly outperformed the China Shanghai Composite, with impressive returns and stable financial metrics, indicating robust growth potential.

Cheng Du Sheng Nuo Biotec Hits Day High with 6.26% Surge

Cheng Du Sheng Nuo Biotec Co. has demonstrated strong market performance, gaining 6.26% on September 30, 2025. Over the past year, it achieved a remarkable return of 113.23%, significantly outperforming the China Shanghai Composite. The company maintains a competitive edge, supported by substantial profit growth of 62.8%.

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

10.55%

EBIT Growth (5y)

107.84%

EBIT to Interest (avg)

6.55

Debt to EBITDA (avg)

0.68

Net Debt to Equity (avg)

0.32

Sales to Capital Employed (avg)

0.36

Tax Ratio

17.66%

Dividend Payout Ratio

22.40%

Pledged Shares

Institutional Holding

ROCE (avg)

7.26%

ROE (avg)

9.15%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

5.99

EV to EBIT

42.06

EV to EBITDA

32.69

EV to Capital Employed

4.91

EV to Sales

10.55

PEG Ratio

Dividend Yield

ROCE (Latest)

11.68%

ROE (Latest)

11.78%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bearish

Bollinger Bands

Sideways

Mildly Bullish

Moving Averages

Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

Mildly Bullish

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot

No data for shareholding present.

Shareholding Compare (%holding)

No data for shareholding present.

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 61.43% vs 2.74% in Jun 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 688.68% vs -13.11% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "151.10",
          "val2": "93.60",
          "chgp": "61.43%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "60.40",
          "val2": "11.30",
          "chgp": "434.51%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "3.80",
          "val2": "2.30",
          "chgp": "65.22%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "41.80",
          "val2": "5.30",
          "chgp": "688.68%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "325.50%",
          "val2": "37.00%",
          "chgp": "28.85%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 4.73% vs 10.23% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -29.16% vs 8.99% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "451.40",
          "val2": "431.00",
          "chgp": "4.73%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "101.10",
          "val2": "105.20",
          "chgp": "-3.90%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "12.00",
          "val2": "9.30",
          "chgp": "29.03%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.30",
          "val2": "0.30",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "49.80",
          "val2": "70.30",
          "chgp": "-29.16%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "145.20%",
          "val2": "176.50%",
          "chgp": "-3.13%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Jun'25

Jun'24

Change(%)

Net Sales

151.10

93.60

61.43%

Operating Profit (PBDIT) excl Other Income

60.40

11.30

434.51%

Interest

3.80

2.30

65.22%

Exceptional Items

-0.00

0.00

Consolidate Net Profit

41.80

5.30

688.68%

Operating Profit Margin (Excl OI)

325.50%

37.00%

28.85%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Jun 2025 is 61.43% vs 2.74% in Jun 2024

Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 688.68% vs -13.11% in Jun 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

451.40

431.00

4.73%

Operating Profit (PBDIT) excl Other Income

101.10

105.20

-3.90%

Interest

12.00

9.30

29.03%

Exceptional Items

0.30

Consolidate Net Profit

49.80

70.30

-29.16%

Operating Profit Margin (Excl OI)

145.20%

176.50%

-3.13%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 4.73% vs 10.23% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -29.16% vs 8.99% in Dec 2023

All Annual Results

Company CV

About Cheng Du Sheng Nuo Biotec Co., Ltd.

Cheng Du Sheng Nuo Biotec Co., Ltd.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available

Cheng Du Sheng Nuo Biotec Co., Ltd.

1Day

52 Week

CASH

FII

DII

Promoter

MarketsMojo — Loved in India, Now Global

Dashboard

With ROE of 11.78%, it has a fair valuation with a 5.99 Price to Book Value

Market Beating performance in long term as well as near term

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Cheng Du Sheng Nuo Biotec Hits Day High with 6.74% Surge

Cheng Du Sheng Nuo Biotec Hits Day High with 6.26% Surge

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Annual Results Snapshot (Consolidated) - Dec'24

About Cheng Du Sheng Nuo Biotec Co., Ltd.

Company Coordinates